Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Katakami, Naoto; Mita, Tomoya; Yoshii, Hidenori; Shiraiwa, Toshihiko; Yasuda, Tetsuyuki; Okada, Yosuke; Kurozumi, Akira; Hatazaki, Masahiro; Kaneto, Hideaki; Osonoi, Takeshi; Yamamoto, Tohru; Kuribayashi, Nobuichi; Maeda, Kazuhisa; Yokoyama, Hiroyuki; Kosugi, Ken’ichirou; Ohtoshi, Kentaro; Hayashi, Isao; Sumitani, Satoru; Tsugawa, Mamiko; Kato, Ken; Nakamura, Tadashi; Kawashima, Seiichiro; Sato, Yasunori; Watada, Hirotaka; Komiyama, Kanki; Shimizu, Tomoaki; Kamei, Shinji; Kinoshita, Tomoe; Shimoda, Masashi; Saito, Makoto; Fujiki, Nobuhiro; Shimizu, Seiko; Umayahara, Yutaka; Irie, Yoshifumi; Kataoka, Ryuho; Kiyohara, Yutaka; Ohashi, Makoto; Ryomoto, Kayoko; Takahi, Yuko; Fujishima, Yuya; Fujita, Yukari; Fukuhara, Atsunori; Fukui, Kenji; Hosokawa, Yohei; Imagawa, Akihisa; Iwahashi, Hiromi; Mukai, Kosuke; Katsura, Takashi; Kawamori, Dan; Kimura, Tomohiko; Kobayashi, Sachiko; Kozawa, Junji; Kubo, Fumiyo; Maeda, Norikazu; Matsuoka, Taka‐aki; Miyashita, Kazuo; Nakata, Shinsuke; Ninomiya, Hiroyo; Nishizawa, Hitoshi; Okuno, Yasuhisa; Otsuki, Michio; Sakamoto, Fumie; Sasaki, Shimaru; Satō, Iwao; Shimo, Nobuo; Shimomura, Iichiro; Takahara, Mitsuyoshi; Takano, Teruo; Tokunaga, Akiteru; Uno, Shigeyuki; Yamaoka, Mitsuaki; Yoneda, S.; Hajime, Mushiake; Koikawa, Kenji; Kuno, Fumi; Matsushita, Hiroshi; Narisawa, Manabu; Tanaka, Kazunari; Sugai, Kuniaki; Torimoto, Katsuji

doi:10.1186/s12933-023-01879-4

Cited by 7 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SGLT2 inhibition has been shown to improve arterial stiffness. A meta-analysis comparing the PWV between the SGLT2 inhibitors-dapagliflozin and empagliflozin-versus placebo found that SGLT2 inhibitors reduced PWV by 0.76 m/s [40], while an observational study with tofogliflozin showed a worsening of arterial stiffness in non-tofogliflozin but not in patients on tofogliflozin [41]. Further details of the impact of SGLT2 inhibitors on vascular function measurements are presented in Supplementary Table S1.…”

Section: Effects Of Sglt2 Inhibitors On Vascular Functionmentioning

confidence: 99%

Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future

Chee,

Dalan

2024

Biomedicines

View full text Add to dashboard Cite

Cardiovascular disease (CVD) and kidney disease are the main causes of morbidity and mortality in type 2 diabetes mellitus (T2DM). Globally, the incidence of T2DM continues to rise. A substantial increase in the burden of CVD and renal disease, alongside the socioeconomic implications, would be anticipated. Adopting a purely glucose-centric approach focusing only on glycemic targets is no longer adequate to mitigate the cardiovascular risks in T2DM. In the past decade, significant advancement has been achieved in expanding the pharmaceutical options for T2DM, with novel agents such as the sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide receptor agonists (GLP-1 RAs) demonstrating robust evidence in cardiorenal protection. Combinatorial approaches comprising multiple pharmacotherapies combined in a single agent are an emerging and promising way to not only enhance patient adherence and improve glycemic control but also to achieve the potential synergistic effects for greater cardiorenal protection. In this review, we provide an update on the novel antidiabetic agents in the past decade, with an appraisal of the mechanisms contributing to cardiorenal protection. Additionally, we offer a glimpse into the landscape of T2DM management in the near future by providing a comprehensive summary of upcoming agents in early-phase trials.

show abstract

Section: Effects Of Sglt2 Inhibitors On Vascular Functionmentioning

confidence: 99%

Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future

Chee,

Dalan

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

On the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects?

Scisciola,

Olivieri,

Ambrosino

et al. 2023

Ageing Research Reviews

View full text Add to dashboard Cite

Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort

Higashikawa,

Ito,

Mizuno

et al. 2024

Medicine

View full text Add to dashboard Cite

Patients with type 2 diabetes mellitus are frequently hospitalized for heart failure. The ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E/e’), measured by echocardiography, is a simple and convenient indicator of diastolic dysfunction. Various large clinical trials have reported that sodium glucose transporter-2 inhibitor therapy reduced cardiovascular events and hospitalizations in heart failure patients. We examined the effect of tofogliflozin on various physiological and cardiac function. A retrospective analysis was performed on elderly patients aged 65 years or older with type 2 diabetes mellitus attending Himi Municipal Hospital who were taking oral tofogliflozin 20 mg/day. Measurement of physiological and hormonal variables, blood sampling, and echocardiographic evaluations at 0, 1, 3, and 6 months were performed on those with ejection fraction (EF) of 40% or greater at the time of treatment. Statistical analysis was performed using t-tests and mixed-effects models, with brain natriuretic peptide less than or not less than 100 pg/mL, estimated glomerular filtration rate (eGFR) less than or not less than 50 mL/min/1.73 m2, and diuretics administered or not. Hypoglycemic effects were observed at 0, 1, 3, and 6 months. At each time point, EF was retained and E/e’ was significantly reduced. On the other hand, most physiological parameters and laboratory results showed no clinical abnormalities. Mixed-effects models showed time-dependent reduction of E/e’ in high/low brain natriuretic peptide, high/low eGFR, with or without diuretics between baseline and at 6 months. The interaction with time was significant in high/low eGFR. Tofogliflozin was shown to improve E/e’, a measure of diastolic function, while maintaining EF, with hypoglycemic effects and no clinical side effects.

show abstract

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Cited by 7 publications

References 45 publications

Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future

Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future

On the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects?

Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort

Contact Info

Product

Resources

About